Impact of PEGylation on Repeat Dosing: Balancing Immune Responses & Therapeutic Efficacy in LNP Delivery
Time: 1:10 pm
day: Conference Agenda
Details:
- Outlining how Orna Therapeutic’s LNP therapeutic programs focusing on linking safety assessment and immune response evaluation
- Exploring immunogenicity assessment strategies including anti-particle and anti-transgene assays, plus cytokine/chemokine biomarker analysis
- Advancing toxicology considerations for next-generation LNPs and how integrated safety–immunogenicity data informs safer design decisions.
Speakers:
